Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy
Clinical trial NCT03381729 · TERMINATED
Trial details
- NCT number
- NCT03381729
- Sponsor
- Novartis Gene Therapies
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-14
- Primary completion
- 2021-11-18
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.